Novo Nordisk: partnership around Mallya in Japan
(CercleFinance.com) - Health2Sync, a healthcare platform, announced on Tuesday that it has signed a partnership in Japan with Denmark's Novo Nordisk and France's Biocorp to integrate Mallya technology, a connected device dedicated to insulin pens.
Under the terms of the agreement, the 350,000 Japanese patients using the Health2Sync application will be able to automatically synchronise the data recorded from the Mallya sensor.
The device, developed by Biocorp and marketed in Japan by Novo Nordisk, is designed for insulin pens to track doses injected and improve compliance for people with diabetes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Under the terms of the agreement, the 350,000 Japanese patients using the Health2Sync application will be able to automatically synchronise the data recorded from the Mallya sensor.
The device, developed by Biocorp and marketed in Japan by Novo Nordisk, is designed for insulin pens to track doses injected and improve compliance for people with diabetes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.